• Wondering if Bio-Techne's current share price lines up with its underlying worth or if the market is missing something.
• The stock last closed at US$53.51, with returns of 5.0% over 30 days, 6.6% over 1 year, and longer term figures such as a 32.3% decline over 3 years and a 47.7% decline over 5 years that many investors will want to factor into risk and reward expectations.
• Recent trading performance, including a 10.3% decline over the past week and a 10.3% decline year to date, gives useful context for anyone weighing up whether current levels reflect caution or renewed interest in the stock. These moves often lead investors to recheck both the quality of the business and how its price compares to fundamentals.
• Bio-Techne currently has a valuation score of 3 out of 6. The next step is a closer look at the main valuation methods investors tend to rely on, along with a different way of thinking about value that ties everything together at the end of this article.

Approach 1: Bio-Techne Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting them back to today’s value.

For Bio-Techne, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $205.7 million. Analysts provide forecasts out to 2027, with Simply Wall St extending those projections further. Within the model, free cash flow is projected to reach about $715.4 million in 2035, with interim annual figures between 2026 and 2035 discounted back to today based on those cash flow projections.

Pulling these discounted estimates together, the DCF model points to an intrinsic value of about $71.81 per share, compared with the recent share price of $53.51. This implies the shares trade at roughly a 25.5% discount to the model’s estimate of fair value, and the stock therefore screens as undervalued on this method.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Bio-Techne is undervalued by 25.5%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Approach 2: Bio-Techne Price vs Earnings

For a profitable company, the P/E ratio is often a useful shorthand for how much investors are paying for each dollar of earnings. It ties directly to what you receive as an owner, earnings per share, and lets you compare that price tag with other options in the same space.

What counts as a “normal” or “fair” P/E depends on what investors expect for future growth and how much risk they see in those earnings. Higher expected growth or lower perceived risk can support a higher P/E, while slower growth or higher uncertainty tends to justify a lower one.

Bio-Techne currently trades on a P/E of 103.28x. That sits well above the Life Sciences industry average of 34.40x and the peer average of 19.81x. To go a step further, Simply Wall St calculates a proprietary “Fair Ratio” for Bio-Techne of 22.70x. This metric is tailored to the company, taking into account factors such as earnings growth, risks, profit margins, market cap and its industry, rather than relying only on broad peer or sector comparisons.

Comparing the current P/E of 103.28x with the Fair Ratio of 22.70x suggests the shares look overvalued on this earnings based view.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Bio-Techne Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so here is an introduction to Narratives, which are simple stories you choose to believe about a company that sit behind the numbers such as fair value, and estimates for future revenue, earnings and margins.

A Narrative links what you think is happening in Bio-Techne's business, such as funding risks or growth in cell and gene therapy tools, to a specific forecast and then to a fair value. This allows you to see whether that story points to a higher or lower value than today’s share price.

On Simply Wall St's Community page, Narratives are an accessible tool used by many investors to compare their own view of fair value with the current price. They also update automatically as new earnings releases, news and analyst assumptions come through.

For Bio-Techne, one investor might align with a more cautious Narrative that points to a fair value around US$56.78, while another might lean toward a more optimistic Narrative closer to US$75.00. Comparing each of these to the latest share price can help you decide how the stock may fit within your overall portfolio approach.

Do you think there's more to the story for Bio-Techne? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.